Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVC Industries sales rise 28.9% to $31.6 mil. in first quarter, paced by Fields of Nature.

This article was originally published in The Tan Sheet

Executive Summary

IVC INDUSTRIES SALES RISE 28.9% TO $31.6 MIL. IN FIRST QUARTER ended Oct. 31, paced by IVC's best-selling vitamins and supplements line, the Fields of Nature brand, the company reported Dec. 11. Fields of Nature posted revenues of "over 15%" of total sales or approximately $4.7 mil., up from about $2.9 mil. -- 12% of sales -- in the prior-year quarter. IVC is planning to extend the brand with more than a dozen new products early in 1997

You may also be interested in...



UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel